EGFR endocytosis down-regulates binding to EphA2 at the plasma membrane
Journal of Biological Chemistry · 2026-08 · 302 (8) · 113301
DOI: 10.1016/j.jbc.2026.113301 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Biological Chemistry, 2026-08. Verfasst von Jennifer A Rybak und 1 weiteren Autor:innen. Beteiligte Einrichtung: Genome Sciences and Technology Graduate Program, University of Tennessee, Knoxville, Tennessee, USA. Hauptthemen laut MEDLINE: Endocytosis, ErbB Receptors, Receptor, EphA2, Cell Membrane. Die Arbeit nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIGMS NIH HHS, National Institute of General Medical Sciences.
Abstract (Originalsprache)
The epidermal growth factor receptor (EGFR) is a membrane protein that is essential to growth, differentiation, and survival in healthy cells. Misregulation of EGFR causes these pathways to function abnormally, leading to tumorigenesis. There are several therapeutics targeting EGFR at the clinic. Unfortunately, EGFR-driven tumors often develop resistance to therapeutics, hampering long-term cancer treatment with EGFR inhibitors. Overexpression of the receptor EphA2 is a common mechanism of EGFR therapeutic resistance. Importantly, EGFR and EphA2 interact at the plasma membrane, but the factors that control this interaction are poorly understood. Here, we investigate how EGFR and EphA2 interact functionally and physically. Immunofluorescence and proximity ligation data indicate that EGFR-EphA2 interactions rapidly decrease after EGFR activation with EGF. Inhibition of endocytosis blocked the effect of EGF on co-localization between both receptors, indicating that endocytosis of EGFR impairs its ability to form hetero-complexes with EphA2. Pharmacological inhibition of EGFR with tyrosine kinase inhibitors was only partially able to block this effect. Our data indicate that endocytosis is an important negative regulatory factor that impacts the levels of EGFR-EphA2 complexes. This information has implications for EGFR drug resistance in cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Genome Sciences and Technology Graduate Program, University of Tennessee, Knoxville, Tennessee, USA.
- Department of Biochemistry & Cellular and Molecular Biology, University of Tennessee, Knoxville, Tennessee, USA. Electronic address: fbarrera@utk.edu.
Förderung
- NIGMS NIH HHS
- National Institute of General Medical Sciences
Zitieren
APA
Rybak, J. A., & Barrera, F. N. (2026). EGFR endocytosis down-regulates binding to EphA2 at the plasma membrane. Journal of Biological Chemistry, 302(8), 113301. https://doi.org/10.1016/j.jbc.2026.113301
Vancouver
Rybak JA, Barrera FN. EGFR endocytosis down-regulates binding to EphA2 at the plasma membrane. Journal of Biological Chemistry. 2026;302(8):113301. doi:10.1016/j.jbc.2026.113301
BibTeX
@article{Rybak2026,
author = {Rybak, Jennifer A and Barrera, Francisco N},
title = {EGFR endocytosis down-regulates binding to EphA2 at the plasma membrane},
journal = {Journal of Biological Chemistry},
year = {2026},
volume = {302},
number = {8},
pages = {113301},
doi = {10.1016/j.jbc.2026.113301}
}
EUVIMED